{"symbol":"REGN","fiscalQuarter":"Q3-2021","reportDate":"2021-11-04","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2021","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.69%","keyNumbers":[{"metric":"EPS","actual":"$15.37","expected":"N/A","surprise":"+56.64%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on advancing our pipeline."],"summary":"Management expressed satisfaction with the earnings per share results, highlighting the strength of their product pipeline. However, they did not provide specific future guidance."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance indicates robust profitability, but the stock's slight decline of 0.69% suggests that investors may have been expecting more comprehensive guidance or revenue details. The lack of revenue data and future guidance could lead to uncertainty among investors moving forward.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2021 earnings: EPS beat expectations. Stock down 0.69%. Full breakdown."}}